Followers | 1330 |
Posts | 251588 |
Boards Moderated | 49 |
Alias Born | 12/07/2009 |
Thursday, September 02, 2021 8:23:23 AM
TRACON Pharmaceuticals, Inc.
Thu, September 2, 2021, 8:05 AM
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Wells Fargo Virtual Healthcare Conference on September 9, 2021 at 12:40pm Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at http://www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
Company Contact:
Investor Contact:
Mark Wiggins
Brian Ritchie
Chief Business Officer
LifeSci Advisors LLC
(858) 251-3492
(212) 915-2578
mwiggins@traconpharma.com
britchie@lifesciadvisors.com
Recent TCON News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/07/2024 09:05:49 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/04/2024 05:15:10 AM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 10/31/2024 09:00:02 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/31/2024 08:45:03 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/31/2024 08:30:04 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/31/2024 08:15:07 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/31/2024 08:15:03 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM